Mylan Can Sell Generic Of Shire's Lialda, Fed. Circ. Confirms
Law360 (April 6, 2018, 9:04 PM EDT) -- A Florida federal judge was within her rights to overturn her earlier finding that Mylan Pharmaceuticals Inc. infringed one of Shire Development LLC's patents for the ulcerative colitis drug Lialda after the Federal Circuit overturned a similar ruling, the appeals court ruled Friday.
Shire had argued that a separate case involving a different defendant's generic shouldn't be binding in Shire's dispute with Mylan, but a three-judge Federal Circuit panel disagreed without further explanation.
Following a four-day bench trial, U.S. District Judge Charlene Edwards Honeywell in January 2017 found Mylan did infringe Shire's U.S. Patent No. 6,773,720 with its generic. But, on Feb. 10,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!